Axsome Therapeutics Inc.
Axsome Therapeutics Reports Preliminary Fourth Quarter and Full Year 2024 Net Revenue
Summary
On January 13, 2025, Axsome Therapeutics, Inc. announced preliminary net product revenue for the fourth quarter and full year of 2024. Auvelity, the company's antidepressant, reported preliminary net product sales of $92.6 million for Q4 and $291.4 million for the full year. Sunosi, used for treating sleep disorders, reported preliminary net product revenue of $25.7 million for Q4 and $93.8 million for the full year. These figures are unaudited and subject to change upon the completion of the company's financial closing procedures.
Profitelligence Alerts
Get alerts for AXSM
Be first to know when Axsome Therapeutics Inc. files with the SEC.
Filing Categories
Exhibits (1)
Advertisement
About Axsome Therapeutics Inc.
Axsome Therapeutics Inc. specializes in the development and commercialization of transformative therapies for central nervous system (CNS) disorders. The company's focus is on addressing unmet medical needs in the fields of depression, migraines, and agitation associated with Alzheimer's disease, among other CNS conditions. Axsome's robust pipeline includes both clinical and preclinical stage compounds, highlighting a commitment to innovation and efficacy. By utilizing novel mechanisms of action, their product candidates aim to offer significant advantages over existing treatments. Axsome Therapeutics plays a crucial role in the pharmaceutical and healthcare sectors, helping reshape treatment paradigms for complex and challenging CNS disorders. Through strategic collaborations and leveraging cutting-edge research methods, the company seeks to provide effective healthcare solutions and improve quality of life for patients globally. Established on a vision to impact lives positively, Axsome continues to advance its clinical programs and regulatory approvals, thereby reinforcing its position in the biotechnology industry.
Official SEC Documents
Advertisement